HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Abstract
Cutaneous T cell lymphomas (CTCLs) represent a heterogeneous group of non-Hodgkin lymphomas that affect the skin. The pathogenesis of these conditions is poorly understood. For example, the signaling mechanisms contributing to the dysregulated growth of the neoplastic T cells are not well defined. Here, we demonstrate that loss of nuclear localization of pro-IL-16 facilitates CTCL cell proliferation by causing a decrease in expression of the cyclin dependent-kinase inhibitor p27Kip1. The decrease in p27Kip1 expression was directly attributable to an increase in expression of S-phase kinase-associated protein 2 (Skp2). Regulation of Skp2 is in part attributed to the nuclear presence of the scaffold protein pro-IL-16. T cells isolated from 11 patients with advanced CTCL, but not those from healthy controls or patients with T cell acute lymphocytic leukemia (T-ALL), demonstrated reduction in nuclear pro-IL-16 levels. Sequence analysis identified the presence of mutations in the 5' end of the PDZ1 region of pro-IL-16, a domain required for association of pro-IL-16 with the nuclear chaperone HSC70 (also known as HSPA8). HSC70 knockdown led to loss of nuclear translocation by pro-IL-16 and subsequent increases in Skp2 levels and decreases in p27Kip1 levels, which ultimately enhanced T cell proliferation. Thus, our data indicate that advanced CTCL cell growth is facilitated, at least in part, by mutations in the scaffold protein pro-IL-16, which directly regulates Skp2 synthesis.
AuthorsClara Curiel-Lewandrowski, Hisato Yamasaki, Chuan Ping Si, Xiaoyi Jin, Yujun Zhang, Jillian Richmond, Marina Tuzova, Kevin Wilson, Beth Sullivan, David Jones, Nataliya Ryzhenko, Frederick Little, Thomas S Kupper, David M Center, William W Cruikshank
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 121 Issue 12 Pg. 4838-49 (Dec 2011) ISSN: 1558-8238 [Electronic] United States
PMID22080865 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Retracted Publication)
Chemical References
  • CDKN1A protein, human
  • CDKN1B protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • DNA, Neoplasm
  • HSC70 Heat-Shock Proteins
  • HSPA8 protein, human
  • Interleukin-16
  • Neoplasm Proteins
  • Protein Precursors
  • S-Phase Kinase-Associated Proteins
  • interleukin 16 precursor
  • Cyclin-Dependent Kinase Inhibitor p27
Topics
  • Active Transport, Cell Nucleus
  • Aged
  • Aged, 80 and over
  • Amino Acid Sequence
  • CD4-Positive T-Lymphocytes (metabolism, pathology)
  • Cell Cycle (genetics)
  • Cyclin-Dependent Kinase Inhibitor p21 (biosynthesis, genetics)
  • Cyclin-Dependent Kinase Inhibitor p27 (biosynthesis, genetics)
  • DNA, Neoplasm (genetics)
  • Female
  • Gene Expression Regulation, Neoplastic
  • HSC70 Heat-Shock Proteins (physiology)
  • Humans
  • Interleukin-16 (genetics, metabolism)
  • Lymphoma, T-Cell, Cutaneous (genetics, metabolism, pathology)
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Mutation
  • Neoplasm Proteins (genetics, metabolism)
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (pathology)
  • Protein Precursors (genetics, metabolism)
  • Protein Structure, Tertiary
  • S-Phase Kinase-Associated Proteins (biosynthesis, physiology)
  • Sequence Alignment
  • Sequence Analysis, DNA
  • Sequence Analysis, Protein
  • Sequence Homology, Amino Acid
  • Sezary Syndrome (genetics, pathology)
  • Skin Neoplasms (genetics, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: